NO954807L - Terapeutisk anvendelse av hemoglobin ved behandling av blodkarblokkering - Google Patents

Terapeutisk anvendelse av hemoglobin ved behandling av blodkarblokkering

Info

Publication number
NO954807L
NO954807L NO954807A NO954807A NO954807L NO 954807 L NO954807 L NO 954807L NO 954807 A NO954807 A NO 954807A NO 954807 A NO954807 A NO 954807A NO 954807 L NO954807 L NO 954807L
Authority
NO
Norway
Prior art keywords
hemoglobin
treatment
blood vessel
therapeutic use
reduction
Prior art date
Application number
NO954807A
Other languages
English (en)
Other versions
NO954807D0 (no
Inventor
Jack E Mckenzie
Kenneth E Burhop
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/350,204 external-priority patent/US6458762B1/en
Application filed by Baxter Int filed Critical Baxter Int
Publication of NO954807D0 publication Critical patent/NO954807D0/no
Publication of NO954807L publication Critical patent/NO954807L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Administrering av lave doser av hemoglobin minimaliserer skade på myo- kardiet etter blokkering og reduserer signifikant reperfusjonsskade. Hemo- globin oppviser en farmakologisk effekt ved å øke perfusJon og blokkere de molekylære virkninger som fører til permanent skade etter en iskemisk episode. Ytterligere fordeler inklu- derer en reduksjon av antallet post- iskemiske arytmier, reduksjon av fore- komsten av restenose og forbedret kontraktil funksjon i risikoområdet.
NO954807A 1994-03-28 1995-11-27 Terapeutisk anvendelse av hemoglobin ved behandling av blodkarblokkering NO954807L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21853694A 1994-03-28 1994-03-28
US08/350,204 US6458762B1 (en) 1994-03-28 1994-12-02 Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
PCT/US1995/003788 WO1995026195A1 (en) 1994-03-28 1995-03-27 Therapeutic use of hemoglobin in the treatment of blood vessel blockage

Publications (2)

Publication Number Publication Date
NO954807D0 NO954807D0 (no) 1995-11-27
NO954807L true NO954807L (no) 1995-11-27

Family

ID=26913008

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954807A NO954807L (no) 1994-03-28 1995-11-27 Terapeutisk anvendelse av hemoglobin ved behandling av blodkarblokkering

Country Status (9)

Country Link
EP (1) EP0700298B1 (no)
JP (1) JPH08511279A (no)
AT (1) ATE243040T1 (no)
AU (1) AU692249B2 (no)
CA (1) CA2163743A1 (no)
DE (1) DE69531086T2 (no)
ES (1) ES2202355T3 (no)
NO (1) NO954807L (no)
WO (1) WO1995026195A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854209A (en) 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
DK0815138T3 (da) * 1995-03-23 2002-12-23 Biopure Corp Stabil polymeriseret hæmoglobin-blod-erstatning
JPH10501823A (ja) * 1995-04-10 1998-02-17 バクスター、インターナショナル、インコーポレイテッド クモ膜下出血の治療における架橋ヘモグロビンの使用
WO2006107107A1 (ja) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87707A (en) * 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
IS4198A (is) * 1993-08-13 1995-02-14 Somatogen, Inc Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða

Also Published As

Publication number Publication date
NO954807D0 (no) 1995-11-27
EP0700298A1 (en) 1996-03-13
ATE243040T1 (de) 2003-07-15
CA2163743A1 (en) 1995-10-05
EP0700298B1 (en) 2003-06-18
JPH08511279A (ja) 1996-11-26
DE69531086T2 (de) 2004-04-01
ES2202355T3 (es) 2004-04-01
DE69531086D1 (de) 2003-07-24
WO1995026195A1 (en) 1995-10-05
AU2196795A (en) 1995-10-17
AU692249B2 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
ATE144704T1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
FR2621818B1 (fr) Medicament comprenant l'association de polymixine b, de netilmicine et d'amphotericine b administre par vaporisation
NO954807D0 (no) Terapeutisk anvendelse av hemoglobin ved behandling av blodkarblokkering
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
CA2091134A1 (en) Therapeutic agent for threatened abortion
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
ATE193451T1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
王有根 Aspirin and Heart-attack (2)
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
BR9811402A (pt) Uso topicamente ou em outro modo administrado, de endipalene em qualquer concentração e em qualquer solvente
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
袁兆庄 et al. STUDIES ON TABELLAE INDIGO NATURALIS IN TREATMENT OF PSORIASIS
RU99122488A (ru) Способ лечения рака эндометрия
Pratesi et al. Eledoisin and bradykinin—Differences in the effects of bradykinin and eledoisin on circulation in skeletal muscles and skin in man
SE8903117D0 (sv) Laekemedel omfattande antamanid
TakayukiOhtsubo et al. ENDOSCOPIC POLYPECTOMY FOR PACEMAKER PATIENTS
张鹰 et al. CHINESE MEDICINAL THERAPY FOR POSTBURN RESIDUAL ULCER—CLINICAL OBSERVATION ON 48 HEALED CASES
陈宝兴 et al. THE USE OF “THYROID PILL” IN THE TREATMENT OF BENIGN NODULES OF THE THYROID——CLINICAL OBSERVATION AND EXPERIMENTAL STUDY
杨荫昌 et al. POINT INJECTION COMBINED WITH ELECTRO-ACUPUNCTURE IN TREATMENT OF 300 CASES OF FACIAL PARALYSIS PERIPHERICA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application